GlassScriptPhysician profile
Steven Prager
NPI 1952304842
$9,324.03
in general payments reported to CMS, 2019-2025
36 companies · $1,984 in 2025
The $1,984 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $23.34 · 2021: $947 · 2022: $2,123 · 2023: $2,086 · 2024: $2,044 · 2025: $1,984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,937 · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,936.77 |
| Education | $176.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,864.15 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $1,209.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,027.99 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Incyte Corporation | $617.05 | 2022-2025 | Opzelura, Opzelura, Iclusig |
| Regeneron Healthcare Solutions, INC. | $356.20 | 2024-2025 | Dupixent |
| Amgen INC. | $338.87 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $271.31 | 2021-2025 | Cuvitru |
| Novartis Pharmaceuticals Corporation | $253.59 | 2022-2025 | |
| Genentech USA, INC. | $248.35 | 2021-2025 | Xolair |
| Pharming Healthcare, INC. | $224.20 | 2022-2024 | Ruconest |
| Pfizer INC. | $191.38 | 2021-2024 | |
| Optinose US, INC. | $184.15 | 2022-2025 | |
| Ars Pharmaceuticals Operations, INC. | $163.92 | 2025 | Neffy |
| Grifols USA, LLC | $160.35 | 2021-2025 | Xembify |
| Blueprint Medicines Corporation | $141.15 | 2022-2025 | Ayvakit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $117.00 | 2019 | |
| Octapharma USA, INC. | $110.91 | 2024 | Cutaquig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.52 | 2022 | |
| Csl Behring | $87.08 | 2020-2025 | Hizentra, Haegarda |
| Leo Pharma INC. | $67.81 | 2025 | Anzupgo |
| Dermavant Sciences, INC. | $63.77 | 2023-2024 | Vtama |
| Horizon Therapeutics Plc | $54.70 | 2021 | |
| Mylan Specialty L.P. | $53.56 | 2021-2022 | |
| Hospira, INC. | $45.55 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $42.64 | 2020-2022 | |
| Covis Pharma Gmbh | $40.26 | 2021 | |
| Abbvie INC. | $38.86 | 2022 | |
| Sanofi-Aventis U.S. LLC | $37.53 | 2021 | |
| Merck Sharp & Dohme LLC | $33.18 | 2023 | |
| Kaleo, INC. | $32.81 | 2021 | |
| Uswm, LLC | $28.69 | 2021 | |
| Aimmune Therapeutics, INC. | $24.99 | 2022 | |
| Paratek Pharmaceuticals, INC. | $23.68 | 2025 | Xhance |
| Organon LLC | $21.40 | 2025 | Vtama |
| Greer Laboratories, INC. | $18.75 | 2024 | Oralair |
| Biocryst US Sales Co., LLC | $18.70 | 2024 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Prager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.